StocksMediumUpdated×2•Originally published 3 November 2026•Updated 3 November 2026•
1 min read
Teva Pharmaceutical Raises 2026 Guidance Following Strong Q3 Results
Key Facts
1Teva Pharmaceutical reported Q3 profits that exceeded analyst estimates.
Teva Pharmaceutical raised its full-year 2026 revenue and earnings guidance. The company reported quarterly revenue of $4.395 billion and adjusted earnings per share of $0.86, which Reuters reported exceeded analyst estimates by $0.14 per share.
Teva Pharmaceutical shares closed at $40.7 on November 2, 2026. During that session, the stock reached a high of $42 and a low of $40.63.